Understanding Shareholder Rights and Voting Structure
Shareholder rights are essential to understanding how companies operate, especially in a fast-evolving field like biotechnology. This is particularly relevant for companies such as Nanobiotix, which is making waves with avant-garde therapeutic techniques aimed at enhancing treatment outcomes. Knowing the number of voting rights associated with shares is crucial for investors looking to grasp their influence in corporate decisions.
Current Share Capital and Voting Rights
As of a recent update, the total number of shares outstanding stands at 47,426,851. This translates to approximately 49,207,475 total theoretical voting rights. However, the actual voting rights that can be exercised in meetings are slightly less, culminating at around 49,185,357. Understanding these figures helps investors gauge the power they hold with their shares.
About Nanobiotix
Nanobiotix is a pioneering biotechnology firm founded in 2003 and has made significant strides in the therapeutic space since its inception. Based in Paris, the company focuses on revolutionary, physics-based approaches to oncology and treatments for disorders of the central nervous system.
Since its listing on the Euronext Paris in 2012, followed by its entry into the Nasdaq Global Select Market in December 2020, Nanobiotix has showcased its commitment to pushing the bounds of medical innovation. This dedication to expanding possibilities is at the heart of their philosophy and is underscored by their impressive portfolio of over 25 patent families covering diverse nanotechnology applications.
The Importance of Voting Rights
For investors in Nanobiotix, the governance of the company is critical. Voting rights empower them to influence significant decisions, from corporate strategies to leadership changes. Companies often have different classes of shares that can vary in voting rights, and understanding these can provide insights into the dynamics of control within the firm.
Future Outlook for Nanobiotix
As Nanobiotix continues to explore innovative solutions in healthcare, its shareholders play a vital role in shaping its future. The pathway to advanced treatments hinges not just on scientific breakthroughs, but also on the active participation of its investors in governance. By understanding their rights and responsibilities, shareholders can better navigate the evolving landscape of biotechnology investments.
For those interested in learning more or getting involved, Nanobiotix has resources available on its website. The connection between patient outcomes and shareholder engagement is becoming more pronounced, emphasizing the integrated role investors play in the success of biotechnology firms.
Frequently Asked Questions
What is the current number of outstanding shares for Nanobiotix?
The company currently has 47,426,851 shares outstanding.
How many voting rights are available to shareholders?
There are 49,207,475 theoretical voting rights and 49,185,357 exercisable voting rights.
What is the primary focus of Nanobiotix?
Nanobiotix focuses on innovative, physics-based approaches to enhance treatment outcomes in oncology and central nervous system disorders.
When was Nanobiotix founded?
Nanobiotix was founded in 2003 and has been listed on several stock exchanges since 2012.
Where is Nanobiotix headquartered?
Nanobiotix is headquartered in Paris, France, and also has a subsidiary in Cambridge, Massachusetts.
